| |
October 16-18, 2023 | Boston, MA
|
|
Today's Big NewsJul 17, 2023 |
| By Nick Paul Taylor Eli Lilly has held the grand reveal of the Alzheimer’s disease trial data it hopes will secure FDA approval for donanemab by the end of the year. The update shows improvements over placebo continued to grow over the course of the study, even after patients stopped taking the drug, but confirmed concerns about safety and the value of treating patients early. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Max Bayer BridgeBio's heart disease drug was victorious in a phase 3 trial, making up for earlier stumbles that threw into question the biotech's cardiorenal aspirations. The company is now planning to submit an approval application to the FDA before the end of the year. |
By James Waldron Novartis is getting full rights to the San Diego-based biotech’s FALCON platform as well as a preclinical therapy for Charcot-Marie-Tooth disease type 1A, a neuromuscular disorder for which there are currently no approved meds. |
Sponsored by Altasciences Optimize Your Drug Development Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drug development over other solid oral dosage forms? Find out! |
|
With the acquisition of XenoTech, BioIVT’s labs have further expanded, allowing for quicker turnaround and more options tailored to your research objectives. View Service Options >>
.png)  |
|
By James Waldron Two years since Novo Nordisk made a push into the ribonucleic acid space spearheaded by its acquisition of Dicerna Pharmaceuticals, the Danish drugmaker has announced a new collaboration to find new ways to apply RNA tech to drug discovery. |
By Gabrielle Masson After losing two Big Pharma partners in quick succession this spring, Sangamo Therapeutics has snagged a deal with Eli Lilly’s Prevail Therapeutics centering around its preclinical neurology adeno-associated virus capsids. |
By James Waldron Three months after a phase 2 fail for its COVID-19 antiviral sent Pardes Biosciences on the hunt for strategic alternatives, the biotech has been bailed out via an acquisition by its key shareholders. |
By Nick Paul Taylor Acumen Pharmaceuticals has early clinical evidence that its Alzheimer’s disease candidate safely reduces amyloid plaque. But while the readout partly addresses concerns about the molecule’s activity, it leaves room to question whether the candidate is sufficiently differentiated from more advanced products. |
By Annalee Armstrong Alnylam’s RNAi approach to Alzheimer’s has reached its target, quickly reducing production of a biomarker linked to a cascade of issues in the brains of people with the neurodegenerative disease. |
By Annalee Armstrong It turns out scientists are taking their CRISPR scissors to Alzheimer’s drug discovery and at the Alzheimer’s Association International Conference in Amsterdam this weekend, researchers around the world got a peek at some of the latest preclinical research. |
By Kevin Dunleavy The FTC has asked Pfizer and Seagen for more information on their proposed $43 billion merger, the Seattle biotech revealed in an SEC filing on Friday. This is the second round of documentation the antitrust regulator has requested from the companies since their deal was announced in March. |
By Conor Hale The FDA has expanded the use of a drug-coated balloon developed by Urotronic for male urinary procedures, which the company describes as one of the first of a new generation of devices in the space. |
By Fraiser Kansteiner Roche and its subsidiaries Genentech and Chugai Pharmaceutical late last week mounted a lawsuit in Massachusetts over claims that Biogen’s proposed biosimilar to Actemra, BIIB800, violates multiple plaintiff-held patents. |
By Dave Muoio The demonstrations will involve "tens of thousands" of union participants seeking increased staffing commitments in their next labor contract. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
